DALLAS, February 16, 2010 /PRNewswire/ --
- ReportsandReports announce to have Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and market growth limited to bone metastases management and emerging supportive care challenges ( http://www.reportsandreports.com/market-reports/pipeline-commercial-insight-s upportive-care-in-oncology-innova/) Market Research Report in its store
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.
Scope - In-depth analysis of the current and future oncology supportive care market across the US, 5EU and Japan, plus a rest of world snapshot - Oncology supportive care therapy sales forecasts for brands, generics, biosimilars and late-phase pipeline candidates from 2008 to 2018 - Assessment of the leading supportive care brands and drug classes to identify key success factors within this sector - Examination of the oncology supportive care pipeline with in-depth clinical and commercial profiles of Phase III candidates
The supportive care market will shrink at a CAGR of -0.6%, with sales dropping from $10.3 billion in 2008 to $9.3 billion in 2018. This is due to the effect of patent expiry and generic/biosimilar erosion, as well ongoing restrictions on use of erythropoietins. Pipeline launches during this time will be insufficient to offset this sales decline.
In 2008, Neulasta (pegfilgrastim; Amgen/Kyowa Kirin) and Neupogen (filgrastim; Amgen/Kyowa Kirin) were the leading supportive care brands, with sales well over $1 billion. Despite facing patent expiry and the increasing threat of biosimilar entry, Neulasta and Neupogen will remain in the top three in 2018, along with Prolia (denosumab; Amgen).
Growth in the market will come mainly from expanded use of current products into new indications and markets. The current pipeline is relatively sparse, however, the greatest breakthrough will occur via Prolia (denosumab; Amgen) for bone metastases. The greatest future growth will come from development in emerging supportive care challenges.
Reasons to Purchase - Quantify the performance of each of the marketed oncology supportive care brands in the seven major markets over the period 2008 to 2018 - Acquire a detailed account of oncology supportive care brand dynamics and the events that drive and limit their market growth - Benchmark the oncology supportive care brands against their generics/biosimilars and align their 7MM performance with a rest of world snapshot Related Reports - What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline - Abraxis BioScience, Inc.-Detailed Product Pipeline - Accentia Biopharmaceuticals Inc-Detailed Product Pipeline
ReportsandReports, comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third-party reseller of market research reports, employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients. We also provide 24/7 online and offline support to our customers.
Contact: Ms. Sunita 7557 Rambler road Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 E-Mail: firstname.lastname@example.org http://www.reportsandreports.com/
Copyright©2010 PR Newswire.
All rights reserved